Literature DB >> 8070581

Expression and regulation of human and rat phosphodiesterase type IV isogenes.

P Engels1, K Fichtel, H Lübbert.   

Abstract

Type IV phosphodiesterases (PDE IV) specifically hydrolyze cAMP and are inhibited by rolipram. RT-PCR was applied to analyze the expression patterns of mRNAs for four cloned human and rat phosphodiesterase type IV isogenes (PDE IV-A, -B, -C and -D). Although these patterns were mostly coincident for the human and rat PDE IV genes, some differences were found between the two species. PDE IV-A expression was detectable in human blood but not in rat blood, suggesting a species-specific difference in the expression of this PDE IV isogene. PDE IV-C was neither detected in human or rat blood nor in different cell populations of the human immune system. It is further demonstrated that the PDE IV isogene expression is differentially regulated by cAMP in different cell types.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070581     DOI: 10.1016/0014-5793(94)00788-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

1.  Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D.

Authors:  G Hansen; S Jin; D T Umetsu; M Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity.

Authors:  Miran Kenk; James T Thackeray; Stephanie L Thorn; Karan Dhami; Benjamin J Chow; Kathy J Ascah; Jean N DaSilva; Rob S Beanlands
Journal:  J Nucl Cardiol       Date:  2010-02-25       Impact factor: 5.952

Review 3.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

4.  Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.

Authors:  J E Souness; M Griffin; C Maslen; K Ebsworth; L C Scott; K Pollock; M N Palfreyman; J A Karlsson
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

5.  Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.

Authors:  I Verde; G Vandecasteele; F Lezoualc'h; R Fischmeister
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

6.  Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism.

Authors:  Claire Jacob; Corinne Szilagyi; Janet M Allen; Claude Bertrand; Vincent Lagente
Journal:  Br J Pharmacol       Date:  2004-08-16       Impact factor: 8.739

7.  Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells.

Authors:  X Jiang; J Li; M Paskind; P M Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

8.  Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

Authors:  M Takahashi; R Terwilliger; C Lane; P S Mezes; M Conti; R S Duman
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

Review 9.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.